Jeff has served as chief executive officer of Surface Oncology since February 2018. Previously, he served as Surface’s chief business officer from February 2017 to February 2018. Prior to Surface, he served as chief financial officer of Voyager Therapeutics where he was one of the members of the founding management team. While at Voyager, he oversaw business development, business operations, finance, investor and public relations, and played a leading role in the establishment of Voyager’s strategic partnership with Sanofi Genzyme as well as its initial public offering. Previously, Jeff spent nearly a decade in investment banking where he was most recently a managing director at Evercore Partners, advising on more than $100 billion in strategic transactions in the biopharma industry. He began his career as a research scientist and holds master’s degrees in microbiology/immunology, pathology and business administration from the University of Rochester. In addition to his role at Surface, Jeff also serves on the board of Vaccinex, Inc.